Lineage Cell Therapeutics, Inc. Cash Flow Statement
LCTX|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$19M
FY2025
Free Cash Flow
-$19M
FY2025
Capital Expenditures
$522,000
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Lineage Cell Therapeutics, Inc. used $19M in operating cash flow and negative free cash flow of $19M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$63.5M | -$18.6M | -$21.5M | -$43.0M | -$20.6M | -$11.7M | -$46.0M | -$20.0M | -$47.0M | -$36.4M | -$43.9M | -$21.4M | -$16.5M | -$11.2M | -$5.1M |
| Depreciation & Amortization | $699.0K | $587.0K | $562.0K | $663.0K | $823.0K | $1.0M | $1.1M | $947.0K | $1.1M | $1.1M | $657.0K | $386.5K | $373.3K | $138.7K | $34.6K |
| Operating Cash Flow | -$18.9M | -$23.1M | -$28.6M | -$23.6M | -$19.8M | -$31.9M | -$30.9M | -$30.5M | -$44.5M | -$38.9M | -$29.5M | -$19.7M | -$13.6M | -$7.7M | -$4.3M |
| Capital Expenditures | $522.0K | $565.0K | $674.0K | $340.0K | $64.0K | $440.0K | $556.0K | $1.3M | $1.2M | $483.0K | $2.3M | $400.8K | $960.3K | $220.8K | $61.3K |
| Free Cash Flow | -$19.4M | -$23.7M | -$29.2M | -$23.9M | -$19.8M | -$32.4M | -$31.4M | -$31.8M | -$45.8M | -$39.3M | -$31.8M | -$20.1M | -$14.6M | -$8.0M | -$4.3M |
| FCF Margin | -133.6% | -249.0% | -326.9% | -550.6% | -1085.3% | -921.4% | -630.3% | -920.9% | -650.7% | -750.1% | -716.9% | -512.9% | -328.2% | -214.5% | -224.5% |